(Q37329315)

English

Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

scientific article published on 19 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

18

object named as

Maryam Fouladi

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Henry Seth Friedman

15

object named as

Henry S Friedman

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

Sridharan Gururangan

2

object named as

Sridharan Gururangan

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

Roger E McLendon

4

object named as

Roger E McLendon

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Richard Gilbertson

10

object named as

Richard J Gilbertson

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

17

object named as

Larry E Kun

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Arzu Onar-Thomas

5

object named as

Arzu Onar-Thomas

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Jason Fangusaro

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Tina Young Poussaint

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Katherine E Warren

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Shengjie Wu

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Roger J Packer

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Anu Banerjee

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Regina Jakacki

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Amar Gajjar

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stewart Goldman

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ian F Pollack

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

James M Boyett

16

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

19 September 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

119

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

23

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

4180-4187

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

VEGF inhibition, hypertension, and renal toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Anti-angiogenic therapies for children with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Osteonecrosis of the jaw and bevacizumab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Adverse effects of anticancer agents that target the VEGF pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Intricacies of bevacizumab-induced toxicities and their management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Susceptibility-Weighted MR Imaging: A Review of Clinical Applications in Children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Vascular endothelial growth factor (VEGF) inhibition--a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

A perivascular niche for brain tumor stem cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Vascular endothelial growth factor and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

VEGF blocking therapy in the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

6 September 2017

Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Genetic repression of mouse VEGF expression regulates coagulation cascade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Pneumothorax after bevacizumab-containing chemotherapy: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Vascular endothelial growth factor: much more than an angiogenesis factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Feasibility and tolerability of bevacizumab in children with primary CNS tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3835419

2 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal Bevacizumab Injection Therapy for Persistent Macular Edema After Idiopathic Macular Epiretinal Membrane Surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China

1 reference

https://pubmed.ncbi.nlm.nih.gov/24104527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28343

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37329315&oldid=2212422086"